Mrs Ashli Westfall, MA, CCC/SLP | |
100 Wurtland Ave, Wurtland, KY 41144-1445 | |
(606) 836-0931 | |
(606) 833-5605 |
Full Name | Mrs Ashli Westfall |
---|---|
Gender | Female |
Speciality | Speech-language Pathologist |
Location | 100 Wurtland Ave, Wurtland, Kentucky |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1548627656 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
235Z00000X | Speech-language Pathologist | 2918 (Kentucky) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Ashli Westfall, MA, CCC/SLP 2358 State Route 3307, Greenup, KY 41144-8824 Ph: (606) 836-0931 | Mrs Ashli Westfall, MA, CCC/SLP 100 Wurtland Ave, Wurtland, KY 41144-1445 Ph: (606) 836-0931 |
News Archive
More than 68 percent of Americans 65 and older - 80 percent age 75 and over - have hypertension (high blood pressure), according to a 2010 report by the Centers for Disease Control. Left untreated, this chronic condition can lead to stroke, heart attack, heart failure or premature death. Researchers at UMDNJ-Robert Wood Johnson Medical School have shown in a follow-up to the landmark clinical trial, Systolic Hypertension in the Elderly Program (SHEP), that the use of antihypertensive drug therapy is associated with longer life expectancy.
Validic, the healthcare industry's leading digital health platform, announced today that it has secured a $12.5 million Series B round led by Kaiser Permanente Ventures, the corporate venture capital arm of Kaiser Permanente. The funding will continue to fuel Validic's rapid growth.
The World Health Organization (WHO), meeting in Geneva have now decided that more research needs to be carried out on Smallpox.
Cubist Pharmaceuticals, Inc. today announced the approval of its supplemental new drug application (sNDA) by the U.S. Food and Drug Administration for ENTEREG (alvimopan).
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the two double blind, randomized, placebo controlled, Phase 3 clinical trials for apaziquone did not meet their primary endpoint of a statistically significant difference in the rate of tumor recurrence at 2 years between the two arms.
› Verified 4 days ago